As expected, amyloid- or tau-negative individuals showed slower cognitive decline compared with their amyloid-positive or tau-positive counterparts, but glycan positivity was a significant negative prognostic factor for future cognition in the amyloid-/tau-negative groups. Here, MAPT is linked to Mental deterioration.